Ken Griffin Ptc Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$30.39 - $37.66 $188,418 - $233,491	6,200 Added 72.09%	14,800 $549,000
Q2 2024 Aug 14, 2024	SELL	$24.69 - $40.12 $2.27 Million - $3.69 Million	-92,000 Reduced 91.45%	8,600 $262,000
Q1 2024 May 15, 2024	BUY	$24.15 - $31.95 $1.93 Million - $2.56 Million	80,000 Added 388.35%	100,600 $2.93 Million
Q4 2023 Feb 14, 2024	BUY	$18.07 - $29.37 $225,875 - $367,125	12,500 Added 154.32%	20,600 $567,000
Q3 2023 Nov 14, 2023	SELL	$22.41 - $41.99 $132,219 - $247,741	-5,900 Reduced 42.14%	8,100 $181,000
Q2 2023 Aug 14, 2023	SELL	$40.4 - $59.1 $662,560 - $969,240	-16,400 Reduced 53.95%	14,000 $569,000
Q1 2023 May 15, 2023	SELL	$38.16 - $48.86 $87,767 - $112,378	-2,300 Reduced 7.03%	30,400 $1.47 Million
Q4 2022 Feb 14, 2023	BUY	$33.53 - $54.79 $144,179 - $235,597	4,300 Added 15.14%	32,700 $1.25 Million
Q3 2022 Nov 14, 2022	BUY	$41.85 - $53.85 $397,575 - $511,575	9,500 Added 50.26%	28,400 $1.43 Million

222

78.1M

144K

58.7K

Ticker PTCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,541,000
Market Cap $3.14B
Description
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.